# DESCRIPTION

## BACKGROUND

### Field of the Invention

- define field of invention

### Related Art

- summarize adaptive immune response
- describe limitations of T cell-dependent response
- motivate T-independent response

## SUMMARY

- introduce T-independent immune response
- summarize method and composition

## DETAILED DESCRIPTION

- describe hybrid protein composition
- describe heterologous antigen composition
- describe FliC flagellin protein
- describe administration of filaments
- describe adjuvants and vaccine composition
- describe nucleic acid preparation and expression

### Example 1

- describe design of hFliC protein
- describe production and purification of recombinant proteins
- describe molecular modeling of FliC and hFliC filaments
- describe polymerization of hFliC or FliC
- describe circular dichroism
- describe negative stain transmission electron microscopy
- describe ELISA of hybrid flagellin
- describe design of DENV2 recombinant IgA
- describe production and purification of DENV2 recombinant IgA
- describe immunogold labeling of hybrid flagellin filaments
- describe B cell crosslinking
- describe immunization protocol
- describe ELISA for quantification of antibody titers

### Example 2

- test FliC as vaccine scaffold for TI antigens
- engineer native FliC by replacing D3 domain with Dengue virus serotype 2 Envelope glycoprotein
- describe design and analysis of hybrid flagellin protein
- express and purify hybrid protein using baculovirus expression system
- characterize hybrid flagellin filaments
- show binding of hFliC to DENV2 specific monoclonal IgA antibody
- determine placement of DENV2 E portion relative to rest of filament
- show humoral immune response in non-restricted mouse models
- describe in vivo immunization protocol used
- show that hybrid flagellin filaments are able to crosslink BCR in vitro
- show humoral immune response in TI mouse model
- produce and purify recombinant FliC and DENV2
- further characterize hFliC filaments
- predict molecular model of hFliC filament
- form filaments in high molar ammonium sulfate or sodium citrate
- evaluate filaments using negative stain transmission electron microscopy
- confirm antigenicity of DENV2 E domain
- test immunogenicity of monomeric and polymeric hFliC in vivo
- determine ability of hFliC filaments to crosslink BCRs
- test potential of polymeric vaccine to induce TI responses in T cell repertoire-restricted model
- discuss significance of hFliC filaments in inducing antibody response
- discuss advantages of reengineering FliC for vaccine development
- discuss limitations of current DENV vaccines
- propose strategy for developing universal DENV vaccine

## CONCLUSIONS

- summarize hybrid protein filaments as vaccine scaffold

